Genetics and Its Use in Alzheimer’s Disease
Psychopharmacology Bulletin · 12.08.2025 · 40 (4) · 132-144
DOI: 10.64719/pb.4144 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychopharmacology Bulletin, online erschienen am 12.08.2025. Verfasst von Joseph H. Lee und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Demenz
Abstract (Originalsprache)
How useful is genetics to a clinician who treats patients with Alzheimer’s disease (AD)? Even though much has been learned about the genetics of AD, given the current state of knowledge, the application of genetics to clinical practice is limited. Three genes (amyloid precursor protein [APP], presenilin 1, and presenilin 2) are primarily responsible for only part of early-onset AD, and the apolipoprotein E (APOE) gene elevates risk but does not confer risk deterministically. In addition, several candidate chromosomal regions are being investigated now. To accurately determine a genetic profile so that it can be used in a clinical setting as a screening or diagnostic tool, much research is needed. Psychopharmacology Bulletin. 2007;40(4):132-144.
Zitieren
APA
Lee, J. H., Mayeux, D. A. R., MD, & MSC (2025). Genetics and Its Use in Alzheimer’s Disease. Psychopharmacology Bulletin, 40(4), 132-144. https://doi.org/10.64719/pb.4144
Vancouver
Lee JH, Mayeux DAR, MD, MSC. Genetics and Its Use in Alzheimer’s Disease. Psychopharmacology Bulletin. 2025;40(4):132-144. doi:10.64719/pb.4144
BibTeX
@article{Lee2025,
author = {Lee, Joseph H. and Mayeux, DRPH and Richard and MD and MSC},
title = {Genetics and Its Use in Alzheimer’s Disease},
journal = {Psychopharmacology Bulletin},
year = {2025},
volume = {40},
number = {4},
pages = {132--144},
doi = {10.64719/pb.4144}
}
EUVIMED